SK172197A3 - Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same - Google Patents

Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same Download PDF

Info

Publication number: SK172197A3
Authority: SK; Slovakia
Prior art keywords: compound; formula; angiotensin; dyspeptic symptoms; pharmaceutical composition
Prior art date: 1995-06-19

Application number

SK1721-97A

Other languages

English (en)

Slovak (sk)

Inventor

Lars Fandriks

Anders Pettersson

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-19

Filing date

1996-06-10

Publication date

1998-07-08

1996-06-10 Application filed by Astra Ab filed Critical Astra Ab

1998-07-08 Publication of SK172197A3 publication Critical patent/SK172197A3/sk

Links

208000024891 symptom Diseases 0.000 title claims abstract description 21
230000000694 effects Effects 0.000 title claims description 11
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title abstract description 4
150000001875 compounds Chemical class 0.000 claims abstract description 23
238000011282 treatment Methods 0.000 claims abstract description 9
238000000034 method Methods 0.000 claims abstract description 8
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000011321 prophylaxis Methods 0.000 abstract 1
239000002253 acid Substances 0.000 description 13
241001465754 Metazoa Species 0.000 description 7
201000006549 dyspepsia Diseases 0.000 description 7
230000003472 neutralizing effect Effects 0.000 description 7
230000036454 renin-angiotensin system Effects 0.000 description 6
239000002083 C09CA01 - Losartan Substances 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
229960004773 losartan Drugs 0.000 description 5
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000006386 neutralization reaction Methods 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
125000000896 monocarboxylic acid group Chemical group 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
102000008873 Angiotensin II receptor Human genes 0.000 description 2
108050000824 Angiotensin II receptor Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
229940069428 antacid Drugs 0.000 description 2
239000003159 antacid agent Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
229960004349 candesartan cilexetil Drugs 0.000 description 2
230000002183 duodenal effect Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003087 receptor blocking agent Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
0 *C1CCCCC1 Chemical compound *C1CCCCC1 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
102000001838 Angiotensin II receptor type 1 Human genes 0.000 description 1
108050009086 Angiotensin II receptor type 1 Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
239000002053 C09CA06 - Candesartan Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
102000010913 Type 1 Angiotensin Receptor Human genes 0.000 description 1
108010062481 Type 1 Angiotensin Receptor Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960000932 candesartan Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
229960005132 cisapride Drugs 0.000 description 1
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
229960002198 irbesartan Drugs 0.000 description 1
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000036407 pain Effects 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000008569 process Effects 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Liquid Crystal Substances (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SK1721-97A 1995-06-19 1996-06-10 Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same SK172197A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9502219A SE9502219D0 (sv)	1995-06-19	1995-06-19	Novel medical use
PCT/SE1996/000758 WO1997000070A1 (fr)	1995-06-19	1996-06-10	Nouvel usage medical

Publications (1)

Publication Number	Publication Date
SK172197A3 true SK172197A3 (en)	1998-07-08

Family

ID=20398663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1721-97A SK172197A3 (en)	1995-06-19	1996-06-10	Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same

Country Status (28)

Country	Link
US (1)	US6096772A (fr)
EP (1)	EP0840607B1 (fr)
JP (1)	JPH11507921A (fr)
KR (1)	KR19990023021A (fr)
CN (1)	CN1091595C (fr)
AT (1)	ATE214925T1 (fr)
AU (1)	AU706660B2 (fr)
BR (1)	BR9608472A (fr)
CA (1)	CA2225175A1 (fr)
CZ (1)	CZ289400B6 (fr)
DE (1)	DE69620186T2 (fr)
DK (1)	DK0840607T3 (fr)
EE (1)	EE03385B1 (fr)
ES (1)	ES2173294T3 (fr)
HK (1)	HK1010152A1 (fr)
HU (1)	HUP9901448A3 (fr)
IL (1)	IL122659A (fr)
IS (1)	IS4619A (fr)
MY (1)	MY114716A (fr)
NO (1)	NO975922D0 (fr)
NZ (1)	NZ310606A (fr)
PT (1)	PT840607E (fr)
RU (1)	RU2209064C2 (fr)
SE (1)	SE9502219D0 (fr)
SK (1)	SK172197A3 (fr)
UA (1)	UA55387C2 (fr)
WO (1)	WO1997000070A1 (fr)
ZA (1)	ZA964690B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
SE9800550D0 (sv) *	1998-02-24	1998-02-24	A & Science Invest Ab	A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
BR0102252B1 (pt) *	2001-04-10	2013-10-22		Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US7413751B2 (en) *	2001-10-25	2008-08-19	Depomed, Inc.	Methods of treatment using a gastric retained losartan dosage
US7271269B2 (en) *	2003-01-30	2007-09-18	Lek Pharmaceuticals D.D.	Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
PL1750862T3 (pl)	2004-06-04	2011-06-30	Teva Pharma	Kompozycja farmaceutyczna zawierająca irbesartan
US8979838B2 (en)	2010-05-24	2015-03-17	Arthrocare Corporation	Symmetric switching electrode method and related system
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1334092C (fr) *	1986-07-11	1995-01-24	David John Carini	Imidazoles bloquant les recepteurs de l'angiotensine ii
US5138069A (en) *	1986-07-11	1992-08-11	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking imidazoles
US5196444A (en) *	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2263638A (en) *	1992-01-28	1993-08-04	Merck & Co Inc	Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists
US5250558A (en) *	1992-01-28	1993-10-05	Merck & Co., Inc.	Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB2263637A (en) *	1992-01-28	1993-08-04	Merck & Co Inc	Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
GB2263639A (en) *	1992-01-28	1993-08-04	Merck & Co Inc	Substituted pyrimidinones as neurotensin antagonists
GB2263635A (en) *	1992-01-28	1993-08-04	Merck & Co Inc	Substitiuted triazoles as neurotensin antagonists
DE4203872A1 (de) *	1992-02-11	1993-08-12	Thomae Gmbh Dr K	Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5212195A (en) *	1992-05-13	1993-05-18	Syntex (U.S.A.) Inc.	Substituted indole antagonists derivatives which are angiotensin II
US5538991A (en) *	1994-09-14	1996-07-23	Merck & Co., Inc.	Endothelin antagonists bearing 5-membered heterocyclic amides

1995
- 1995-06-19 SE SE9502219A patent/SE9502219D0/xx unknown
1996
- 1996-06-05 ZA ZA964690A patent/ZA964690B/xx unknown
- 1996-06-10 JP JP9502982A patent/JPH11507921A/ja active Pending
- 1996-06-10 ES ES96918965T patent/ES2173294T3/es not_active Expired - Lifetime
- 1996-06-10 SK SK1721-97A patent/SK172197A3/sk unknown
- 1996-06-10 EE EE9700366A patent/EE03385B1/xx not_active IP Right Cessation
- 1996-06-10 US US08/702,522 patent/US6096772A/en not_active Expired - Fee Related
- 1996-06-10 HU HU9901448A patent/HUP9901448A3/hu unknown
- 1996-06-10 EP EP96918965A patent/EP0840607B1/fr not_active Expired - Lifetime
- 1996-06-10 PT PT96918965T patent/PT840607E/pt unknown
- 1996-06-10 IL IL12265996A patent/IL122659A/xx not_active IP Right Cessation
- 1996-06-10 WO PCT/SE1996/000758 patent/WO1997000070A1/fr not_active Application Discontinuation
- 1996-06-10 AT AT96918965T patent/ATE214925T1/de not_active IP Right Cessation
- 1996-06-10 CZ CZ19973730A patent/CZ289400B6/cs not_active IP Right Cessation
- 1996-06-10 CN CN96196137A patent/CN1091595C/zh not_active Expired - Fee Related
- 1996-06-10 NZ NZ310606A patent/NZ310606A/en unknown
- 1996-06-10 DK DK96918965T patent/DK0840607T3/da active
- 1996-06-10 BR BR9608472A patent/BR9608472A/pt not_active Application Discontinuation
- 1996-06-10 CA CA002225175A patent/CA2225175A1/fr not_active Abandoned
- 1996-06-10 AU AU11840/97A patent/AU706660B2/en not_active Ceased
- 1996-06-10 DE DE69620186T patent/DE69620186T2/de not_active Expired - Fee Related
- 1996-06-10 RU RU98101105/14A patent/RU2209064C2/ru not_active IP Right Cessation
- 1996-06-10 KR KR1019970709491A patent/KR19990023021A/ko not_active Application Discontinuation
- 1996-06-19 MY MYPI96002480A patent/MY114716A/en unknown
- 1996-10-06 UA UA97126085A patent/UA55387C2/uk unknown
1997
- 1997-11-25 IS IS4619A patent/IS4619A/is unknown
- 1997-12-16 NO NO975922A patent/NO975922D0/no not_active Application Discontinuation
1998
- 1998-10-14 HK HK98111234A patent/HK1010152A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
UA55387C2 (uk)	2003-04-15
JPH11507921A (ja)	1999-07-13
CZ373097A3 (cs)	1998-05-13
DE69620186D1 (de)	2002-05-02
ES2173294T3 (es)	2002-10-16
EP0840607B1 (fr)	2002-03-27
ATE214925T1 (de)	2002-04-15
DE69620186T2 (de)	2002-10-31
DK0840607T3 (da)	2002-05-06
CN1091595C (zh)	2002-10-02
IL122659A (en)	2003-01-12
NZ310606A (en)	2001-03-30
IL122659A0 (en)	1998-08-16
RU2209064C2 (ru)	2003-07-27
MX9710002A (es)	1998-07-31
US6096772A (en)	2000-08-01
EE03385B1 (et)	2001-04-16
CZ289400B6 (cs)	2002-01-16
CA2225175A1 (fr)	1997-01-03
EP0840607A1 (fr)	1998-05-13
AU706660B2 (en)	1999-06-17
NO975922L (no)	1997-12-16
ZA964690B (en)	1996-12-19
IS4619A (is)	1997-11-25
KR19990023021A (ko)	1999-03-25
MY114716A (en)	2002-12-31
HK1010152A1 (en)	1999-06-17
NO975922D0 (no)	1997-12-16
HUP9901448A3 (en)	2002-03-28
HUP9901448A2 (hu)	2000-04-28
EE9700366A (et)	1998-06-15
BR9608472A (pt)	1998-12-29
PT840607E (pt)	2002-09-30
SE9502219D0 (sv)	1995-06-19
CN1192681A (zh)	1998-09-09
AU1184097A (en)	1997-01-15
WO1997000070A1 (fr)	1997-01-03

Publication	Publication Date	Title
RU2345790C2 (ru)	2009-02-10	Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда
JP2002504516A (ja)	2002-02-12	アンギオテンシンｉｉ型２リセプタ作用薬を含む医薬製剤およびその使用
SK172197A3 (en)	1998-07-08	Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same
SK87998A3 (en)	1998-12-02	Novel medical use of an ace-inhibitor for treatment of dyspeptic symptoms
US20120122919A1 (en)	2012-05-17	Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
CA2457982C (fr)	2009-11-03	Utilisation de la nefiracetame dans le traitement de la neurodegenerescence
CA2373881A1 (fr)	2001-01-11	Utilisation d'un antagoniste du recepteur de type 1 de l'angiotensine ii dans la fabrication d'un medicament destine au traitement des complications cardio-vasculaires
NO975221L (no)	1997-11-13	Ny farmakologisk anvendelse av AII-reseptorantagonister
JP2003535897A (ja)	2003-12-02	アンギオテンシンｉｉアンタゴニストの新規使用法
MXPA97010002A (es)	1998-11-09	Nuevo uso medico
DE4339848C2 (de)	1995-11-02	Arzneimittel zur optimierten Behandlung eines erhöhten Blutdrucks und zur Verhütung von Folgeerkrankungen
DE3915236A1 (de)	1990-11-15	Pharmazeutische zubereitung
CN1140996A (zh)	1997-01-22	雷尼替丁和碳酸钙药物复合品